We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into DexCom (DXCM) Q3: Wall Street Projections for Key Metrics
Read MoreHide Full Article
The upcoming report from DexCom (DXCM - Free Report) is expected to reveal quarterly earnings of $0.57 per share, indicating an increase of 26.7% compared to the year-ago period. Analysts forecast revenues of $1.18 billion, representing an increase of 18.4% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain DexCom metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts' assessment points toward 'Revenue- Hardware' reaching $39.65 million. The estimate indicates a year-over-year change of -6.5%.
The average prediction of analysts places 'Revenue- Sensor and other' at $1.14 billion. The estimate points to a change of +19.6% from the year-ago quarter.
It is projected by analysts that the 'Revenue- United States' will reach $843.25 million. The estimate suggests a change of +20.1% year over year.
According to the collective judgment of analysts, 'Revenue- International' should come in at $332.15 million. The estimate points to a change of +13.6% from the year-ago quarter.
Over the past month, shares of DexCom have returned +2.9% versus the Zacks S&P 500 composite's +3.8% change. Currently, DXCM carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insights Into DexCom (DXCM) Q3: Wall Street Projections for Key Metrics
The upcoming report from DexCom (DXCM - Free Report) is expected to reveal quarterly earnings of $0.57 per share, indicating an increase of 26.7% compared to the year-ago period. Analysts forecast revenues of $1.18 billion, representing an increase of 18.4% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain DexCom metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts' assessment points toward 'Revenue- Hardware' reaching $39.65 million. The estimate indicates a year-over-year change of -6.5%.
The average prediction of analysts places 'Revenue- Sensor and other' at $1.14 billion. The estimate points to a change of +19.6% from the year-ago quarter.
It is projected by analysts that the 'Revenue- United States' will reach $843.25 million. The estimate suggests a change of +20.1% year over year.
According to the collective judgment of analysts, 'Revenue- International' should come in at $332.15 million. The estimate points to a change of +13.6% from the year-ago quarter.
View all Key Company Metrics for DexCom here>>>Over the past month, shares of DexCom have returned +2.9% versus the Zacks S&P 500 composite's +3.8% change. Currently, DXCM carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .